A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata

Trink, Anna; Sorbellini, Elisabetta; Bezzola, Paola; Rodella, Luigi Fabrizio; Rezzani, Rita; Ramot, Yuval; Rinaldi, Fabio

doi:10.1111/bjd.12397

Cited by 234 publications

(215 citation statements)

References 17 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…Study by Trink et al, a randomized, double-blind, placebo-and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. 31 In a study by Singh, role of platelet-rich plasma in chronic alopecia areata: Our centre experience.…”

Section: Discussionmentioning

confidence: 99%

A clinical study on alopecia areata

Ninama¹,

Mahajan²,

Bilimoria³

et al. 2018

Int J Res Dermatol

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is a common auto-immune condition, causing hair loss. This disease has limited treatment modalities. Through this study, comparison between established modalities of treatment such as oral mini pulse therapy, intralesional corticosteroids and platelet-rich plasma (PRP) as a newer modality has been done. The objective of the study was to evaluate the efficacy and safety of various treatment modalities in alopecia areata.Methods: 45 patients with alopecia areata presenting to the OPD of Dermatology, Dhiraj hospital, Pipariya were included in this study. It was conducted as a randomized prospective study for a period of 16 weeks. After taking informed consent, patients were randomly distributed into three treatment groups. Group 1 patients were treated with Tab. Betamethasone 0.1 mg/kg every Saturday and Sunday, Group 2 was treated with Inj. Triamcinolone acetonide 10 mg/ml for scalp and 2.5 mg/ml for eye brows and face was injected into deep dermis; Group 3 was treated with Dermaroller followed by application of activated platelet rich plasma (PRP). SALT score was calculated at first visit and 16 weeks. Regrowth was calculated using Mac Donald and Null Horis grading Scale at 16 weeks.Results: The SALT score reduced from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2 and 42.32 to 21.12 in Group 3. Mean grade of regrowth of hairs observed was 3.47, 3.80, 2.93 in Group 1, 2, 3 respectively. The results were analysed using paired t test.Conclusions:Intralesional corticosteroids viz. triamcinolone acetonide still remains the first choice of therapy for AA in adults with limited involvement. Systemic corticosteroids give lower response than intralesional steroids. Platelet Rich Plasma (PRP) showed promising results, especially in children and in extensive involvement. Compared to other treatment modalities Inj. PRP is safe and with less side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

A clinical study on alopecia areata

Ninama¹,

Mahajan²,

Bilimoria³

et al. 2018

Int J Res Dermatol

View full text Add to dashboard Cite

show abstract

“…26,27 Systemically, betamethasone and prednisolone are commonly used as mini pulse therapies. 28,29 Other modalities found effective in the treatment of AA include topical minoxidil, 30,31 oral and topical psoralen and ultraviolet A (PUVA), turban PUVA, topical diphenylcyclopropenone as contact-sensitizing immunotherapy, 32 methotrexate, azathioprine, 16 platelet-rich plasma, 33 sulfasalazine, 34 narrow band ultraviolet B, and bexarotene gel. 35 Biologics are ineffective and may cause aggravation during therapy.…”

Section: Mgmjmsmentioning

confidence: 99%

Alopecia Areata: An Update

Jerajani¹,

Rohatgi²,

Agrawal³

2017

MGM Journal of Medical Sciences

View full text Add to dashboard Cite

Alopecia areata (AA) is a very common autoimmune disease that leads to unpredictable, relapsing patchy hair loss. Its chronic pathophysiology is still not fully understood. Hair follicles are not destroyed permanently due to which the potential for regrowth of hair is retained for many years, and is possibly lifelong. Clinical presentation varies from small alopecia patches most commonly on the scalp to full body involvement. Characteristic "swarm of bees" appearance on histopathology is confirmatory in acute cases. A variety of therapeutic options are available, but search for new modalities continues as there is a high relapse rate and a number of side effects associated with the available treatment options.

show abstract

“…The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance [102,103]. New possible offline treatments for AGA, such as topical finasteride, injectable dutasteride, laser therapy and PRP, have recently emerged and have been claimed to have hair growth-promoting or anti-hair loss effects.…”

Section: Emerging Treatmentsmentioning

confidence: 99%

Androgenetic Alopecia: a Review and Emerging Treatments

Alves¹

2017

CRDOA

View full text Add to dashboard Cite

Androgenetic Alopecia (AGA) is the most common noncicatricial alopecia that leads to the progressive miniaturization of the hair follicle. Scalp terminal hairs are converted into vellus hairs, primarily due to two factors: genetic predisposition and hormonal stimulation.The incidence and prevalence of AGA increases with age. The onset of AGA is gradual, and when this pathology progresses, the anagen phase shortens and the telogen phase remains constant. The shedding area varies from patient to patient and is usually most marked at the vertex in men, while women with AGA generally lose hair diffusely over the crown.Topical minoxidil and oral finasteride (5-alpha-reductase type II inhibitor) are the gold-standard therapies for AGA and are currently the only Food and Drug Administration (FDA)-approved drugs for the treatment of AGA.The currently available treatments for AGA are sometimes perceived as having limited effectiveness; therefore, the identification of new therapies for this pathology is of utmost importance.This article aims to review the pathogenesis, diagnosis of AGA and all the new emerging treatments for this entity in order to prevent its progression and improve the results of this pathology.

show abstract

A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata

Abstract: This pilot study, which is the first to investigate the effects of PRP on AA, suggests that PRP may serve as a safe and effective treatment option in AA, and calls for more extensive controlled studies with this method.

Cited by 234 publications

References 17 publications

A clinical study on alopecia areata

A clinical study on alopecia areata

Alopecia Areata: An Update

Androgenetic Alopecia: a Review and Emerging Treatments

Contact Info

Product

Resources

About